Form 4: Intellia Therapeutics Director Brian Goff Reports Significant Equity Grant and Option Acquisition

Intellia Therapeutics, Inc. Director Brian Goff has reported the acquisition of 8,000 restricted stock units and 11,450 stock options, granted as part of his compensation, effective June 11, 2025.

Summary

• Brian Goff, a Director of Intellia Therapeutics, Inc. (NTLA), reported transactions occurring on June 11, 2025, as filed with the SEC on June 13, 2025.
• He acquired 8,000 shares of common stock in the form of restricted stock units (RSUs) at a price of $0.00. These RSUs represent a contingent right to receive one share of common stock for each unit.
• Following this transaction, Mr. Goff beneficially owns 23,409 shares of common stock.
• Additionally, Mr. Goff was granted 11,450 stock options with an exercise price of $8.37 per share.
• These stock options have an expiration date of June 10, 2035, and will vest in full on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders following the grant date.
• The transactions were made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged purchase or sale plan.

Sentiment

Score: 7

Explanation: The acquisition of equity by a director, even if a grant, generally signals continued commitment and aligns interests with shareholders, which is a positive indicator. The pre-planned nature (10b5-1) makes it a routine event, but still positive for insider alignment.

Positives

• The acquisition of 8,000 restricted stock units and 11,450 stock options by a director indicates continued alignment of management's interests with shareholders.
• The grant of equity compensation is a standard practice to incentivize directors and retain talent, fostering long-term commitment.

Negatives

• The shares acquired are restricted stock units granted at $0.00, and the options are also a grant, not an open market purchase, which means there is no direct cash outlay by the director for these specific acquisitions at the time of grant.

Risks

• The Power of Attorney document includes an indemnification clause where Brian Goff agrees to indemnify the attorney-in-fact and the Company against any demand, damage, loss, cost, or expense arising from false or misleading information provided by him, highlighting the importance of accurate information from reporting persons.

Future Outlook

The vesting schedule for the granted stock options indicates that they will vest in full on the earlier of the first anniversary of the grant date (June 11, 2026) or the date of the next annual meeting of stockholders following the grant date, aligning the director's long-term incentives with future company performance.

Industry Context

This Form 4 filing reflects standard executive and director compensation practices within the biotechnology and pharmaceutical industries, where equity grants like restricted stock units and stock options are commonly used to attract, retain, and incentivize key personnel, aligning their financial interests with the long-term success of the company.

Corporate Governance

Related Party Transactions

• The acquisition of restricted stock units and stock options by Director Brian Goff from Intellia Therapeutics, Inc. constitutes a related party transaction, as it involves compensation from the company to an insider.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with shareholder value creation, potentially fostering long-term growth.
• Employees: May signal stability and confidence in the company's future, potentially boosting morale.

Next Steps

• The 11,450 stock options will vest in full on the earlier of June 11, 2026 (first anniversary of grant date) or the date of the next annual meeting of stockholders following the grant date.

Key Dates

Recommendation

Keywords

Intellia Therapeutics, NTLA, Brian Goff, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Options, Equity Grant, Director Compensation, Rule 10b5-1 Plan, Biotechnology, Pharmaceuticals